Metformin Down-regulates Secretion via Suppression of Scavenger Receptors in Macrophages |
Hyun, Bobae
(College of Pharmacy, Sahmyook University)
Shin, Seulmee (College of Pharmacy, Sahmyook University) Lee, Aeri (College of Pharmacy, Sahmyook University) Lee, Sungwon (College of Pharmacy, Sahmyook University) Song, Youngcheon (College of Pharmacy, Sahmyook University) Ha, Nam-Joo (College of Pharmacy, Sahmyook University) Cho, Kyung-Hea (Department of Biology, Seoul Women's University) Kim, Kyungjae (College of Pharmacy, Sahmyook University) |
1 | Flegal, K. M., M. D. Carroll, C. L. Ogden, and L. R. Curtin. 2010. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 303: 235-241. DOI |
2 | Bae, N. K., I. S. Kwon, and Y. C. Cho. 2009. Ten year change of body mass index in Korean: 1997-2007. Korean J. Obes. 18: 24-30. |
3 | Mokdad, A. H., E. S. Ford, B. A. Bowman, W. H. Dietz, F. Vinicor, V. S. Bales, and J. S. Marks. 2003. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 289: 76-79. |
4 | Grundy, S. M. 2004. Obesity, metabolic syndrome, and cardiovascular disease. J. Clin. Endocrinol. Metab. 89: 2595-2600. DOI |
5 | Shaw, J. E., R. A. Sicree, and P. Z. Zimmet. 2010. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes. Res. Clin. Pract. 87: 4-14. DOI |
6 | Alberti, K. G. and P. Z. Zimmet. 1998. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet. Med. 15: 539-553 DOI |
7 | Shoelson, S. E., L. Herrero, and A. Naaz. 2007. Obesity, inflammation, and insulin resistance. Gastroenterology 132: 2169-2180. DOI |
8 | Qatanani, M. and M. A. Lazar. 2007. Mechanisms of obesityassociated insulin resistance: many choices on the menu. Genes. Dev. 21: 1443-1455. DOI |
9 | McArdle, M. A., O. M. Finucane, R. M. Connaughton, A. M. McMorrow, and H. M. Roche. 2013. Mechanisms of obesity- induced inflammation and insulin resistance: insights into the emerging role of nutritional strategies. Front. Endocrinol. (Lausanne). 4: 52. |
10 | Olefsky, J. M. and C. K. Glass. 2010. Macrophages, inflammation, and insulin resistance. Annu. Rev. Physiol. 72: 219-246. DOI |
11 | Kim, J. Y. 2010. Patho-/physiological roles of adipose tissue macrophages. BioWave 12: 1-12. |
12 | Chawla, A., K. D. Nguyen, and Y. P. Goh. 2011. Macrophage- mediated inflammation in metabolic disease. Nat. Rev. Immunol. 11: 738-749. DOI |
13 | Osborn, O. and J. M. Olefsky. 2012. The cellular and signaling networks linking the immune system and metabolism in disease. Nat. Med. 18: 363-374. DOI |
14 | Lumeng, C. N., J. L. Bodzin, and A. R. Saltiel. 2007. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J. Clin. Invest. 117: 175-184. DOI |
15 | Patel, P. S., E. D. Buras, and A. Balasubramanyam. 2013. The role of the immune system in obesity and insulin resistance. J. Obes. 2013: 616193. |
16 | Goldstein, J. L., Y. K. Ho, S. K. Basu, and M. S. Brown. 1979. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc. Natl. Acad. Sci. U. S. A. 76: 333-337. DOI |
17 | Ley, K., Y. I. Miller, and C. C. Hedrick. 2011. Monocyte and macrophage dynamics during atherogenesis. Arterioscler. Thromb. Vasc. Biol. 31: 1506-1516. DOI |
18 | Kzhyshkowska, J., C. Neyen, and S. Gordon. 2012. Role of macrophage scavenger receptors in atherosclerosis. Immunobiology 217: 492-502. DOI |
19 | Baranova I. N., R. Kurlander, A. V. Bocharov, T. G. Vishnyakova, Z. Chen, A. T. Remaley, G. Csako, A. P. Patterson, and T. L. Eggerman. 2008. Role of human CD36 in bacterial recognition, phagocytosis, and pathogen-induced JNK-mediated signaling. J. Immunol. 181: 7147-7156. DOI |
20 | Chen, Y., F. Wermeling, J. Sundqvist, A. B. Jonsson, K. Tryggvason, T. Pikkarainen, and M. C. Karlsson. 2010. A regulatory role for macrophage class A scavenger receptors in TLR4-mediated LPS responses. Eur. J. Immunol. 40: 1451-1460. DOI |
21 | Hundal, R. S., M. Krssak, S. Dufour, D. Laurent, V. Lebon, V. Chandramouli, S. E. Inzucchi, W. C. Schumann, K. F. Petersen, B. R. Landau, and G. I. Shulman. 2000. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes. 49: 2063-2069. DOI |
22 | Yu, H., T. Ha, L. Liu, X. Wang, M. Gao, J. Kelley, R. Kao, D. Williams, and C. Li. 2012. Scavenger receptor A (SR-A) is required for LPS-induced TLR4 mediated NF-κB activation in macrophages. Biochim. Biophys. Acta. 1823: 1192-1198. DOI |
23 | Cai, L., Z. Wang, A. Ji, J. M. Meyer, and D. R. van der Westhuyzen. 2012. Scavenger receptor CD36 expression contributes to adipose tissue inflammation and cell death in diet- induced obesity. PLoS One 7: e36785. DOI |
24 | Bailey, C. J. and R. C. Turner. 1996. Metformin. N. Engl. J. Med. 334: 574-579. DOI |
25 | Hundal, R. S. and S. E. Inzucchi. 2003. Metformin: new understandings, new uses. Drugs 63: 1879-1894. DOI |
26 | Correia, S., C. Carvalho, M. S. Santos, R. Seica, C. R. Oliveira, and P. I. Moreira. 2008. Mechanisms of action of metformin in type 2 diabetes and associated complications: an overview. Mini Rev. Med. Chem. 8: 1343-1354. DOI |
27 | Zhou, G., R. Myers, Y. Li, Y. Chen, X. Shen, J. Fenyk- Melody, M. Wu, J. Ventre, T. Doebber, N. Fujii, N. Musi, M. F. Hirshman, L. J. Goodyear, and D. E. Moller. 2001. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108: 1167-1174. DOI |
28 | Nath, N., M. Khan, M. K. Paintlia, I. Singh, M. N. Hoda, and S. Giri. 2009. Metformin attenuated the autoimmune disease of the central nervous system in animal models of multiple sclerosis. J. Immunol. 182: 8005-8014. DOI |
29 | Musi, N., M. F. Hirshman, J. Nygren, M. Svanfeldt, P. Bavenholm, O. Rooyackers, G. Zhou, J. M. Williamson, O. Ljunqvist, S. Efendic, D. E. Moller, A. Thorell, and L. J. Goodyear. 2002. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes. 51: 2074-2081. DOI |
30 | Lee, S. K., J. O. Lee, J. H. Kim, S. J. Kim, G. Y. You, J. W. Moon, J. H. Jung, S. H. Park, K. O. Uhm, J. M. Park, P. G. Suh, and H. S. Kim. 2011. Metformin sensitizes insulin signaling through AMPK-mediated PTEN down-regulation in preadipocyte 3T3-L1 cells. J. Cell. Biochem. 112: 1259-1267. DOI |
31 | Tsoyi, K., H. J. Jang, I. T. Nizamutdinova, Y. M. Kim, Y. S. Lee, H. J. Kim, H. G. Seo, J. H. Lee, and K. C. Chang. 2011. Metformin inhibits HMGB1 release in LPS-treated RAW 264.7 cells and increases survival rate of endotoxaemic mice. Br. J. Pharmacol. 162: 1498-1508. |
32 | Kalariya, N. M., M. Shoeb, N. H. Ansari, S. K. Srivastava, and K. V. Ramana. 2012. Antidiabetic drug metformin suppresses endotoxin-induced uveitis in rats. Invest. Ophthalmol. Vis. Sci. 53: 3431-3440. DOI |
33 | Yuan, H., L. Li, W. Zheng, J. Wan, P. Ge, H. Li, and L. Zhang. 2012. Antidiabetic drug metformin alleviates endotoxin- induced fulminant liver injury in mice. Int. Immunopharmacol. 12: 682-688. DOI |
34 | Kim, H. K. and I. K. Lee. 2006. Endoplasmic reticulum (ER) stress and vascular complication. J. Korean Diabetes. Assoc. 30: 145-150. DOI |
35 | Vila-del Sol, V. and M. Fresno. 2005. Involvement of TNF and NF-kappa B in the transcriptional control of cyclooxygenase- 2 expression by IFN-gamma in macrophages. J. Immunol. 174: 2825-2833. DOI |
36 | Serhan, C. N. and B. Levy. 2003. Success of prostaglandin E2 in structure-function is a challenge for structure-based therapeutics. Proc. Natl. Acad. Sci. U. S. A. 100: 8609-8611. DOI |
37 | Nathan, C. 1997. Inducible nitric oxide synthase: what difference does it make? J. Clin. Invest. 100: 2417-2423. DOI |
38 | Sun, L., J. Liu, D. Cui, J. Li, Y. Yu, L. Ma, and L. Hu. 2010. Anti-inflammatory function of Withangulatin A by targeted inhibiting COX-2 expression via MAPK and NF-kappaB pathways. J. Cell. Biochem. 109: 532-541. |
39 | Dinarello, C. A. 2000. Proinflammatory cytokines. Chest. 118: 503-508. DOI |
40 | Chi, H., S. P. Barry, R. J. Roth, J. J. Wu, E. A. Jones, A. M. Bennett, and R. A. Flavell. 2006. Dynamic regulation of pro- and anti-inflammatory cytokines by MAPK phosphatase 1 (MKP-1) in innate immune responses. Proc. Natl. Acad. Sci. U. S. A. 103: 2274-2279. DOI |
41 | Opal, S. M. and V. A. DePalo. 2000. Anti-inflammatory cytokines. Chest 117: 1162-1172. DOI |
42 | Ma, X. 2001. TNF-alpha and IL-12: a balancing act in macrophage functioning. Microbes. Infect. 3: 121-129. DOI |
43 | Locksley, R. M., N. Killeen, and M. J. Lenardo. 2001. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell. 104: 487-501. DOI |
44 | Maini, R. N. and P. C. Taylor. 2000. Anti-cytokine therapy for rheumatoid arthritis. Annu. Rev. Med. 51: 207-229. DOI |
45 | Hotamisligil, G. S., D. L. Murray, L. N. Choy, and B. M. Spiegelman. 1994. Tumor necrosis factor alpha inhibits signaling from the insulin receptor. Proc. Natl. Acad. Sci. U. S. A. 91: 4854-4858. DOI |
46 | Aggarwal, B. B. 2003. Signalling pathways of the TNF superfamily: a double-edged sword. Nat. Rev. Immunol. 3: 745-756 DOI |
47 | Charles, K. A., H. Kulbe, R. Soper, M. Escorcio-Correia, T. Lawrence, A. Schultheis, P. Chakravarty, R. G. Thompson, G. Kollias, J. F. Smyth, F. R. Balkwill, and T. Hagemann. 2009. The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans. J. Clin. Invest. 119: 3011-3023. DOI |
48 | Ji, Z. Z., Z. Dai, and Y. C. Xu. 2011. A new tumor necrosis factor (TNF)- regulator, lipopolysaccharides-induced TNF- factor, is associated with obesity and insulin resistance. Chin. Med. J (Engl). 124: 177-182. |
49 | Ziccardi, P., F. Nappo, G. Giugliano, K. Esposito, R. Marfella, M. Cioffi, F. D'Andrea, A. M. Molinari, and D. Giugliano. 2002. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation 105: 804-809. DOI |
50 | Simons, P. J., P. S. van den Pangaart, J. M. Aerts, and L. Boon. 2007. Pro-inflammatory delipidizing cytokines reduce adiponectin secretion from human adipocytes without affecting adiponectin oligomerization. J. Endocrinol. 192: 289-299. DOI |
51 | Popa, C., M. G. Netea, P. L. van Riel, J. W. van der Meer, and A. F. Stalenhoef. 2007. The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. J. Lipid. Res. 48: 751-762. DOI |
52 | Kleemann, R., S. Zadelaar, and T. Kooistra. 2008. Cytokines and atherosclerosis: a comprehensive review of studies in mice. Cardiovasc. Res. 79: 360-376. DOI |
53 | Spagnoli, L. G., E. Bonanno, G. Sangiorgi, and A. Mauriello. 2007. Role of inflammation in atherosclerosis. J. Nucl. Med. 48: 1800-1815. DOI |
54 | Skoog, T., W. Dichtl, S. Boquist, C. Skoglund-Andersson, F. Karpe, R. Tang, M. G. Bond, U. de Faire, J. Nilsson, P. Eriksson, and A. Hamsten. 2002. Plasma tumour necrosis factor- alpha and early carotid atherosclerosis in healthy middle- aged men. Eur. Heart. J. 23: 376-383. DOI |
55 | Mei, C. L., Z. J. Chen, Y. H. Liao, Y. F. Wang, H. Y. Peng, and Y. Chen. 2007. Interleukin-10 inhibits the down-regulation of ATP binding cassette transporter A1 by tumour necrosis factor-alpha in THP-1 macrophage-derived foam cells. Cell. Biol. Int. 31: 1456-1461. DOI |
56 | Hashizume, M. and M. Mihara. 2012. Atherogenic effects of TNF-α and IL-6 via up-regulation of scavenger receptors. Cytokine. 58: 424-430. DOI |
57 | Tak, P. P. and G. S. Firestein. 2001. NF-kappaB: a key role in inflammatory diseases. J. Clin. Invest. 107: 7-11 DOI |